DAFNA CAPITAL MANAGEMENT LLC
Q4 2022 Form 13-F
LOS ANGELES, CALIFORNIA
CIK 0001389933
· CRD 129053
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q2 2013
$355.1M Reported Value Total
DAFNA CAPITAL MANAGEMENT, LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $589,457,792, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $1.3B gross asset value
Hedge Fund: $1.3B
Source: Form ADV filed 2026-03-30
Reported value
$355.1M
Quarter over quarter
+1.9%
Holdings
79
Top-10 concentration
50.3%
Filing Structure
Reports holdings for
- Fischel Nathan · File #028-12328 · since Q2 2013
Key People
Form ADV owners & control persons
Nathan Fischel
TRUSTEE
Fariba Fischel Ghodsian
TRUSTEE
Xun Lin
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 14, 2023 |
| Form | 13F-HR |
| Reported value | $355.1M |
| Positions | 79 |
| Change in reported value | -4.5% |
| New positions | 5 |
| Exited positions | 13 |
| Position turnover | 19.6% |
| Top-10 concentration | 50.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
88 | $524.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
82 | $439.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
76 | $430.5M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
74 | $404.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
75 | $362.3M |
|
Q1 2025 13F
Filed May 15, 2025
|
82 | $352.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
81 | $393.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
83 | $423.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
82 | $418.6M |
|
Q1 2024 13F
Filed May 15, 2024
|
71 | $439.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
75 | $417.3M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
74 | $321.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
72 | $365.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $333.5M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
79 | $355.1M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
86 | $371.8M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
88 | $366.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
92 | $383.8M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
85 | $397.7M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
78 | $376.9M |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | XBI SPDR S&P BIOTECH ETF | $47.0M | 13.23% |
| 2 | STXS STEREOTAXIS INC | $28.3M | 7.98% |
| 3 | ASND ASCENDIS PHARMA A/S | $15.9M | 4.48% |
| 4 | KRTX KARUNA THERAPEUTICS INC | $14.2M | 3.99% |
| 5 | IBB ISHARES NASDAQ BIOTECH INDX | $13.5M | 3.79% |
| 6 | ISEE IVERIC BIO INC | $13.0M | 3.65% |
| 7 | XENE XENON PHARMACEUTICALS INC | $12.5M | 3.51% |
| 8 | BPMC BLUEPRINT MEDICINES CORP | $11.4M | 3.22% |
| 9 | RVMD REVOLUTION MEDICINES INC | $11.4M | 3.21% |
| 10 | SNDX SYNDAX PHARMACEUTICALS INC | $11.4M | 3.2% |
| 11 | NBIX NEUROCRINE BIOSCIENCES INC | $8.7M | 2.46% |
| 12 | IDYA IDEAYA BIOSCIENCES INC | $8.5M | 2.4% |
| 13 | CYTK CYTOKINETICS INC | $8.4M | 2.37% |
| 14 | DXCM DEXCOM INC | $7.6M | 2.15% |
| 15 | SAGE SAGE THERAPEUTICS INC | $6.9M | 1.94% |
| 16 | EWTX EDGEWISE THERAPEUTICS INC | $6.9M | 1.93% |
| 17 | NRIX NURIX THERAPEUTICS INC | $6.2M | 1.75% |
| 18 | ACET ADICET BIO INC | $5.6M | 1.59% |
| 19 | FATE FATE THERAPEUTICS INC | $5.6M | 1.57% |
| 20 | BHVN BIOHAVEN LTD | $5.5M | 1.54% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.